Printer Friendly

IMMUNOMEDICS REPORTS ON POTENTIAL DIAGNOSTIC FOR AIDS-RELATED PNEUMONIA

 -- Initial Clinical Findings Presented at
 Society of Nuclear Medicine Annual Meeting --
 TORONTO, June 10 /PRNewswire/ -- At the 40th Annual Meeting of the Society of Nuclear Medicine in Toronto, Immunomedics, Inc. (NASDAQ: IMMU), Morris Plains, New Jersey, announced initial clinical results with an imaging agent for detecting Pneumocystis carinii pneumonia (PCP) in AIDS patients. In a presentation made by Dr. David M. Goldenberg, president of the Garden State Cancer Center and chairman of Immunomedics, an antibody-based imaging agent was 87 percent accurate in detecting the presence or absence of PCP in 15 AIDS patients.
 In the study, an antibody fragment made specifically against PCP was labeled with technetium-99m and injected in the AIDS patients with pneumonia of suspected Pneumocystis carinii origin, who were then imaged with a standard nuclear medicine camera within 24 hours. Conventional lung washing cytology and other imaging methods including chest radiographs and gallium scans were also performed for comparison.
 According to Dr. Goldenberg, "In this study, the antibody imaging agent correctly revealed the presence of PCP in 6 of 7 patients and the absence of PCP in 7 of 8 patients. PCP afflicts up to 80 percent of AIDS patients and is often a major cause of their severe illness and death. This new, simple, non-invasive diagnostic for PCP could potentially provide a more specific test and therefore more appropriate treatment for these patients. It is our intention to expand these trials in order to assess the accuracy and clinical role of this agent."
 Immunomedics conducted this research in conjunction with its collaborators at the garden State cancer center and University Hospital (Newark, NJ), University of Cincinnati and VA Medical Centers (Cincinnati, OH), and the Morristown Memorial Hospital (Morristown, NJ).
 Dr. Stephen Udem, director, Infectious Disease Division, University Hospital, Newark, NJ, added, "These early tests indicate that this imaging agent may enable rapid differentiation between Pneumocystis and other more transmissible diseases, such as tuberculosis. This could allow for quicker and more efficient therapy for these patients."
 PCP is characterized as an opportunistic infection and occurs when the host defense mechanism has been altered or breached by disease or trauma. PCP afflicts over 100,000 patients with AIDS and other immunocompromised conditions, such as those which occur after organ transplantation or cancer chemotherapy. Current detection of PCP requires morphological detection of the infecting organisms in pulmonary material gained by inducing sputum samples or by lung washings.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapuetic agents or toxins to tumors and sites of infections or other diseases. The company currently has two therapeutics and five imaging products in human clinical trials. In addition, the company's colorectal cancer imaging agent, ImmuRAID(TM)-CEA, is under review for marketing approval by the U.S. Food and Drug Administration, as well as by regulatory agencies in Europe and Canada.
 -0- 6/10/93
 /CONTACT: Debra Wasser, director of corporate communications of Immunomedics, 201-605-1330, ext. 113/
 (IMMU)


CO: Immunomedics Inc. ST: New Jersey IN: MTC SU: PDT

TM -- NY003 -- 0450 06/10/93 08:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:538
Previous Article:THIRD 'CRIMEWATCH NEW JERSEY' PROGRAM TO BE AIRED STATEWIDE TUESDAY, JUNE 15, ON CTN 7:00 - 8:00 P.M.; PROGRAM TO FOCUS ON COMMUNITY POLICING
Next Article:CAREMARK ANNOUNCES LETTER OF INTENT TO MANAGE OKLAHOMA CITY CLINIC
Topics:


Related Articles
IMMUNOMEDICS REPORTS FIRST CLINICAL RESULTS OF LYMPHOMA IMAGING AGENT
IMMUNOMEDICS REPORTS LYMPHOMA IMAGING AND THERAPY TEST RESULTS POSITIVE PHASE II STAGING AND THERAPY FINDINGS
IMMUNOMEDICS' LEUKOSCAN ACHIEVES 87% SPECIFICITY IN DETECTING APPENDICITIS
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedic Engages Lehman Brothers As Financial Advisor
Immunomedics and Beckman Coulter Form Joint Venture to Develop Cancer Therapeutics
Dutch Court Upholds Immunomedics' Patent
Dutch court upholds Immunomedics' patent
Patent on positron emission tomography agents awarded to Immunomedics.
Clinical Results With Immunomedics' Infectious Disease Imaging Product Reported at Major Medical Conference.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters